Please read and agree to the
terms and conditions
of this site.
I agree
Medical Technology
/tech
Clear filters and search
Format
photo
Tags
akcea therapeutics
boston blog main
boston top stories
fda
3
×
inotersen
3
×
life sciences
national blog main
national top stories
new york blog main
new york top stories
san diego blog main
san diego top stories
san francisco blog main
san francisco top stories
3
×
alnylam pharmaceuticals
biotech
boston
clinical trials
hereditary transthyretin amyloidosis
patisiran
rna interference
tafamidis
vyndaqel
2025
ad-comm
affimed
allogene therapeutics
amicus therapeutics
andrew fire
approval
apremilast
barry greene
base editing
bio
biogen
biome
blueprint medicineas
boston university
boulder/denver blog main
boulder/denver top stories
What
alnylam
fda
medicine
afternoon
ago
allogene
alnylam’s
approve
approved
awaits
bio
biological
cancer
crispr
crossed
decades
decision
discovered
diversity
drug
fingers
friday
gets
historic
history
hot
immunotherapy
investors
ipo
juno
landmark
making
million
nearly
new
ok
onpattro
patients
patisiran
pharmaceuticals
Language
Current search:
inotersen
×
fda
×
" san francisco top stories "
×
@xconomy.com
5 years ago
Bio Roundup: BIO Diversity, Allogene IPO, CRISPR In Utero & More
@xconomy.com
5 years ago
Alnylam Gets Landmark FDA OK For First-Ever RNAi Drug
@xconomy.com
5 years ago
Patients Have “Fingers Crossed” As Alnylam Awaits Historic FDA Decision